Radient Pharmaceuticals, a developer of in vitro diagnostic (IVD) cancer tests, has sold and shipped its first order of Onko-Sure test kits to a distributor in Brazil.
The distributor will submit the test in Brazilian labs for regulatory approval and clinical validation.
Radient claims, prior to the shipment of these test kits, it has filed for patent protection for Onko-Sure in Brazil.
The Onko-Sure is a 96-well Elisa test kit which detects 19 different cancers.
The test aids physicians to answer clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence.
Radient chairman and CEO Douglas MacLellan said Brazil is key for them in both addressing the cancer challenge in healthcare markets, as well as in establishing a base for expanding Onko-Sure use into the rest of South America.
"We are actively collaborating with our Brazilian partners for regulatory progress and clinical lab adoption," MacLellan said.